TY - JOUR A1 - Endesfelder, Stefanie A1 - Weichelt, Ulrike A1 - Strauß, Evelyn A1 - Schlör, Anja A1 - Sifringer, Marco A1 - Scheuer, Till A1 - Bührer, Christoph A1 - Schmitz, Thomas T1 - Neuroprotection by caffeine in hyperoxia-induced neonatal brain injury JF - International journal of molecular sciences N2 - Sequelae of prematurity triggered by oxidative stress and free radical-mediated tissue damage have coined the term “oxygen radical disease of prematurity”. Caffeine, a potent free radical scavenger and adenosine receptor antagonist, reduces rates of brain damage in preterm infants. In the present study, we investigated the effects of caffeine on oxidative stress markers, anti-oxidative response, inflammation, redox-sensitive transcription factors, apoptosis, and extracellular matrix following the induction of hyperoxia in neonatal rats. The brain of a rat pups at postnatal Day 6 (P6) corresponds to that of a human fetal brain at 28–32 weeks gestation and the neonatal rat is an ideal model in which to investigate effects of oxidative stress and neuroprotection of caffeine on the developing brain. Six-day-old Wistar rats were pre-treated with caffeine and exposed to 80% oxygen for 24 and 48 h. Caffeine reduced oxidative stress marker (heme oxygenase-1, lipid peroxidation, hydrogen peroxide, and glutamate-cysteine ligase catalytic subunit (GCLC)), promoted anti-oxidative response (superoxide dismutase, peroxiredoxin 1, and sulfiredoxin 1), down-regulated pro-inflammatory cytokines, modulated redox-sensitive transcription factor expression (Nrf2/Keap1, and NFκB), reduced pro-apoptotic effectors (poly (ADP-ribose) polymerase-1 (PARP-1), apoptosis inducing factor (AIF), and caspase-3), and diminished extracellular matrix degeneration (matrix metalloproteinases (MMP) 2, and inhibitor of metalloproteinase (TIMP) 1/2). Our study affirms that caffeine is a pleiotropic neuroprotective drug in the developing brain due to its anti-oxidant, anti-inflammatory, and anti-apoptotic properties. KW - anti-oxidative response KW - caffeine KW - hyperoxia KW - oxidative stress KW - preterm infants KW - developing brain Y1 - 2017 U6 - https://doi.org/10.3390/ijms18010187 SN - 1422-0067 SN - 1661-6596 VL - 18 PB - Molecular Diversity Preservation International CY - Basel ER - TY - JOUR A1 - Czarnecka, Malgorzata A1 - Weichelt, Ulrike A1 - Rödiger, Stefan A1 - Hanack, Katja T1 - Novel Anti Double-Stranded Nucleic Acids Full-Length Recombinant Camelid Heavy-Chain Antibody for the Detection of miRNA JF - International Journal of Molecular Sciences N2 - The discovery that certain diseases have specific miRNA signatures which correspond to disease progression opens a new biomarker category. The detection of these small non-coding RNAs is performed routinely using body fluids or tissues with real-time PCR, next-generation sequencing, or amplification-based miRNA assays. Antibody-based detection systems allow an easy onset handling compared to PCR or sequencing and can be considered as alternative methods to support miRNA diagnostic in the future. In this study, we describe the generation of a camelid heavy-chain-only antibody specifically recognizing miRNAs to establish an antibody-based detection method. The generation of nucleic acid-specific binders is a challenge. We selected camelid binders via phage display, expressed them as VHH as well as full-length antibodies, and characterized the binding to several miRNAs from a signature specific for dilated cardiomyopathy. The described workflow can be used to create miRNA-specific binders and establish antibody-based detection methods to provide an additional way to analyze disease-specific miRNA signatures. KW - antibody KW - camelid antibody KW - heavy-chain-only antibody KW - miRNA KW - nucleic acids KW - novel biomarkers Y1 - 2022 U6 - https://doi.org/10.3390/ijms23116275 SN - 1422-0067 VL - 23 SP - 1 EP - 18 PB - MDPI CY - Basel, Schweiz ET - 11 ER - TY - JOUR A1 - Endesfelder, Stefanie A1 - Weichelt, Ulrike A1 - Schiller, Cornelia A1 - Winter, Katja A1 - von Haefen, Clarissa A1 - Bührer, Christoph T1 - Caffeine protects against anticonvulsant-induced impaired neurogenesis in the developing rat brain JF - Neurotoxicity Research N2 - In preterm infants, phenobarbital is the first-line antiepileptic drug for neonatal seizures while caffeine is used for the treatment of apnea. Data from experimental animals suggest that phenobarbital and other anticonvulsants are toxic for the developing brain, while neuroprotective effects have been reported for caffeine both in newborn rodents and preterm human infants. To characterize the interaction of phenobarbital and caffeine in the hippocampus of the developing rodent brain, we examined the effects of both drugs given separately or together on postnatal neurogenesis after administration to neonatal rats throughout postnatal day (P) 4 to P6. Phenobarbital treatment (50 mg/kg) resulted in a significant decrease of proliferative capacity in the dentate gyrus. Phenobarbital also reduced expression of neuronal markers (doublecortin (DCX), calretinin, NeuN), neuronal transcription factors (Pax6, Sox2, Tbr1/2, Prox1), and neurotrophins (NGF, BDNF, NT-3) up to 24 h after the last administration. The phenobarbital-mediated impairment of neurogenesis was largely ameliorated by preconditioning with caffeine (10 mg/kg). In contrast, caffeine alone reduced proliferative capacity and expression of the neuronal markers DCX and NeuN at 6 h, but increased expression of neurotrophins and neuronal transcription factors at 6 and 12 h. These results indicate that administration of phenobarbital during the vulnerable phase of brain development negatively interferes with neuronal development, which can be prevented in part by co-administration of caffeine. KW - Caffeine KW - Developing brain KW - Phenobarbital KW - Preterminfants KW - Hippocampal neurogenesis Y1 - 2018 U6 - https://doi.org/10.1007/s12640-018-9872-8 SN - 1029-8428 SN - 1476-3524 VL - 34 IS - 2 SP - 173 EP - 187 PB - Springer CY - New York ER -